Sotorasib and Interstitial Lung Disease

In this article, we will discuss Sotorasib and Interstitial Lung Disease. So, let’s get started.

Sotorasib and Interstitial Lung Disease (ILD)/Pneumonitis

Sotorasib can cause ILD/pneumonitis that can be fatal. Among 357 patients who received Sotorasib in CodeBreaK 100, ILD/pneumonitis occurred in 0.8% of patients, all cases were
Grade 3 or 4 at onset, and 1 case was fatal. The median time to first onset for ILD/pneumonitis was 2 weeks (range: 2 to 18 weeks). Sotorasib was discontinued due to ILD/pneumonitis in 0.6% of patients. Monitor
patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever).
Immediately withhold Sotorasib in patients with suspected ILD/pneumonitis and permanently discontinue Sotorasib if no other potential causes of ILD/pneumonitis are identified.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.